:: Volume 13, Issue 1 (Winter 2022) ::
Caspian J Intern Med 2022, 13(1): 16-22 Back to browse issues page
Improvement of cognitive deficit of curcumin on scopolamine-induced Alzheimer’s disease models
Guzin Cakmak * , Davut Sinan Kaplan , Caner Yildirim , Hasan Ulusal , Mehmet Tarakcioglu , Zeynel Abidin Öztürk
Gaziantep University, Faculty of Medicine, Department of Internal Medicine, Division of Geriatric Medicine, Gaziantep, Turkey , drguzincakmak@gmail.com
Abstract:   (1235 Views)
Background: It has been suggested that curcumin may be useful in diseases with cognitive dysfunction because it slows the progression and leads to the improvement of cognitive functions. In this study, the protective effects of curcumin on scopolamine-induced rat models of cognitive impairment were evaluated.
Methods: 21 male Wistar Albino rats, 1 year old, 200±25 grams, were included in the study. They were divided into three groups (n: 7 in each group); the untreated control group, scopolamine group, and the group treated with curcumin and then exposed to scopolamine. Animals were evaluated for behavioral tasks with the Morris Water Maze test. Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), total oxidative status (TOS), and total antioxidative status (TAS) were measured in hippocampal tissues. CRP levels were measured in serum specimens.
Results: We found that the length to reach the platform was the highest in the scopolamine group, and the lowest in the curcumin group (p<0.001). Time to reach the platform was the longest in the scopolamine group, and the shortest in the curcumin group (P=0.002). The length to reach the platform was the highest in the scopolamine group, and the lowest in the control group in the probe test (p<0.001). IL-6 levels were higher in the scopolamine group than the curcumin group (P=0.017) and the control group (P=0.005).
Conclusion: We revealed that curcumin provides a protective effect on scopolamine-induced cognitive impairment mimicking Alzheimer's disease.  The use of curcumin for the protection of cognition in individuals at risk of developing AD may be considered.
Keywords: curcumin, scopolamine, Alzheimer’s disease, dementia, Morris Water Maze, inflammation
Full-Text [PDF 245 kb]   (320 Downloads)    
Type of Study: Original Article | Subject: Internal
Received: 2020/10/23 | Accepted: 2021/02/8 | Published: 2022/01/30

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 1 (Winter 2022) Back to browse issues page